Audiogenic seizures (AGS) in genetically epilepsy-prone rats (GEPR) of the moderateseizure substrain (GEPR-3s) were investigated to determine whether norepinephrine (NE) depletion induced by 6-hydroxydopamine (6-OHDA) microinfusion into the locus coeruleus (LC) 
to confirm that they were GEPR-3s.
The seizure severity was scored using the seizurerating scale described by Jobe/20/, which assigns scores from 0 (no seizure) to 9 (generalized tonicseizure with complete hindlimb extension) with each score above 0 representing an increasingly severe seizure. GEPR-3s display seizures characterized by two running phases culminating in clonus of the forelimbs and hindlimbs. Testing for AGS involves placing each rat into a round (40 cm) Plexiglass arena and exposing them to a bell tone of 100 db intensity for 60 seconds. This procedure induces consistent seizures of intensity 3 in GEPR-3s and 9 in GEPR-9s. Only GEPR-3s were used in the present study. The latency to onset of running behavior and convulsion was timed and the seizure severity was scored and recorded for each rat.
Experimental protocol
After preliminary AGS-testing of each rat for confirmation of seizure display, rats were divided into the following two groups" 6-OHDA microinfused (n=38), and saline microinfused (n=7).
Animals from each of these two groups were subsequently divided into the following subgroups" 6-OHDA-infused, LC-grafted (n=19); 6-OHDAinfused, cortex-gratted (n=10); 6-OHDA-infused, sham-grafted (n=9); saline-infused, LC-grafted (n=5); saline-infiased, sham-gratted (n=2). The timing of pretests, microinfusions, post-microinfusion tests, grafting and post-grafting tests are shown in schematic form in Figure 1 . Briefly, animals were pretested upon delivery to insure that they were GEPR-3s. After pretesting, rats were microinfused with either saline or 6 Although only about 40% of the animals treated with 6-OHDA experienced a subsequent increase in seizure severity (see below), all of the examined brains of 6-OHDA treated animals were consistently depleted ofNE (Fig. 2) .
Histology of grafts
An example of an LC graft in an animal of the present study is shown in Figure 3 There were four typical behavioral responses across the treatment groups: 1) rats which displayed an increase in seizure severity following 6-OHDA microinfusion, and a subsequent reduction in seizure severity following grafting (Figure 4a ). This response was called exacerbated/corrected; 2) rats which demonstrated an increase in seizure severity following 6-OHDA microinfusion with no reduction in seizure severity following grafting (Figure 4b ).
This response was called exacerbated/noncorrected; 3) rats which showed no increase in seizure severity after 6-OHDA treatment, but who did show a reduction in seizure severity atter grafting ( Figure  4c ). This response was called nonexacerbated/ corrected; and 4) rats which demonstrated no increase in seizure severity following 6-OHDA microinfusion and no reduction in seizure severity atter grafting (Figure 4d ). This response was called nonexacerbated/noncorrected. The number of animals in each treatment group displaying each of these four responses are indicated in Table 2 . With reference to change in seizure severity following microinfusions of 6-OHDA into the LC, 15 of the 38 animals (39.47%) displayed a significant increase in seizure severity following 6-OHDA treatment (p<0.0418). In the control group, 0 of the 7 had altered seizure severity following saline microinfusion. Figure 5 shows the percentage of animals in which grafting resulted in a reduction of seizure severity. As shown in Figure 5, showed an increase in seizure severity from a score of 3 to a score of 9 by the third test after 6-OHDA. This represents an increase in severity from a moderate clonic seizure to a severe tonic-clonic seizure with full hindlimb extension. Subsequent to grafting fetal LC, the severity of seizures was again reduced from a score of 9 to the previous score of 3. Panel B shows the data from an animal (GEPR-3, sl-#2) who did not show an increase in seizure severity after 6-OHDA but who did show a reduction in seizure severity from a pregraffing score of 3 to a score of 0, representing a complete absence of seizure in response to the audiogenic stimulus. Panel C shows the data from an animal (GEPR-3, s4-#16) who showed an increase in seizure severity following 6-OHDA treatment, but who did not show any reduction in seizure severity up to 12 weeks following grafting of fetal cerebral cortex. Panel D shows the data from an animal (GEPR-3, s3-#24) who did not show an increase in seizure severity following 6-OHDA, nor was there a reduction in seizure severity following grafting. VOLUME 5, NO. 1, 1994 
Treatment groups
The percentage of animals who showed a reduction in seizure severity subsequent to grafting or sham treatment. The incidence of reduction in seizure severity was highest in the 6-OHDA, LC transplanted group (p<0.0167).
that for the entire group (n=l 9) due to the fact that some of these animals were not exacerbated by 6 -OHDA yet all these animals' seizure severity scores were reduced following grafting (i.e., some to below pretest values). Following grafting of LC, seizure scores were significantly lower than both the pretest and post 6-OHDA treatment scores (p<0.05). Latencies to the onset of running behavior and convulsions were not altered subsequent to brain infusions or transplantation in rats of any of the groups. Seizure severity scores (mean of three separate tests + S.E.M.) in all LC grafted animals (n=19, Panel A) and those LC grafted animals which showed a reduction in seizure severity following grafting (n=10, Panel B). In all animals, the pretest score was 3. Panel A: Following 6-OHDA, the severity of seizure in all animals increased significantly from a mean of 3 to 4.7 in the entire group (note, however, that only 39% of these animals were exacerbated following 6-OHDA). The effects of LC grafts on seizure severity across the entire group were not significant in that the scores after grafting were not significantly different from those after 6-OHDA; however, these scores were also not different from the pretest values (*=p<0.05 from pretest scores only, ANOVA [F2,18 5 .06]). Panel B. In those 10 animals which showed reduction in seizure severity, 6-OHDA significantly increased the severity of seizure from 3 to 4.2 (note, however, that not all of these animals were exacerbated following 6-OHDA). After LC grafting, those 10 animals that were corrected had significantly lower seizure severity scores than animals at pretest and following 6-OHDA (*p<0.05 from pretest and post grafting; **p<0.05 from pretest and post 6-OHDA: ANOVA lF2,9 10.37]).
DISCUSSION
It is well documented that seizure severity in the GEPR is inversely correlated with brain NE level /14,20,21,23/. Previous studies in this laboratory/8/ and others/5/have demonstrated that depletion of brain NE in normal rats and GEPR-3s using the catecholamine neurotoxin 6-OHDA results in an increase in seizure severity in a significant number of these animals. In the present study, analysis of NE content in the cortex, an area of the brain which receives the majority of its noradrenergic terminals from the LC, revealed that 6-OHDA microinfusion into the LC caused a 78% reduction in cortical NE. The 46% depletion of NE content in the brainstem as a result of microinfusion of 6-OHDA into the LC is also significant. It should be recognized that the remaining catecholamine nuclei in the brainstem, including those in the diffuse lateral tegmental system, remain intact. 
